Vincristine, bleomycin, mitomycin C, cisplatin combination chemotherapy as additive treatment to radiotherapy in poor risk patients with squamous cell carcinoma of the uterine cervix.
Vermorken
J B
JB
vd Burg
M E
ME
Subandono
A J
AJ
Mangioni
C
C
De Oliveira
C F
CF
Zola
P
P
van Oosterom
A T
AT
Pecorelli
S
S
van Lindert
A C
AC
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000009:adverse effects / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000009:adverse effects / Q000627:therapeutic use; D011878:Radiotherapy / Q000009:adverse effects; D012306:Risk; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
D008937:Mitomycins; D001761:Bleomycin; D016685:Mitomycin; D014750:Vincristine; D002945:Cisplatin